Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.30990
Abstract: In a phase 1 study of pulse/continuous‐dose erlotinib, no patient had disease progression in the central nervous system (CNS). This expansion cohort of the phase 1 study tested the same regimen in a cohort of… read more here.
Keywords: mutant lung; continuous dose; factor receptor; growth factor ... See more keywords
Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles
Sign Up to like & getrecommendations! Published in 2019 at "Pharmaceutical Research"
DOI: 10.1007/s11095-019-2665-9
Abstract: KRAS is the most frequently mutated gene in human cancers. Despite its direct involvement in malignancy and intensive effort, direct inhibition of KRAS via pharmacological inhibitors has been challenging. RNAi induced knockdown using siRNAs against… read more here.
Keywords: mutant lung; kras mutant; cancer; serum albumin ... See more keywords
Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Biochemical and Biophysical Research Communications"
DOI: 10.1016/j.bbrc.2017.04.102
Abstract: Abstract EGFR-mutant lung adenocarcinomas contain a subpopulation of cells that have undergone epithelial-to-mesenchymal transition and can grow independently of EGFR. To kill these cancer cells, we need a novel therapeutic approach other than EGFR inhibitors.… read more here.
Keywords: lung adenocarcinoma; egfr; egfr mutant; mutant lung ... See more keywords
Blocking STAT3 by Pyrvinium Pamoate Causes Metabolic Lethality in KRAS-mutant lung cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Biochemical pharmacology"
DOI: 10.1016/j.bcp.2020.113960
Abstract: Signal transducer and activator of transcription 3 (STAT3) exerts a profound role in regulating mitochondrial function and cellular metabolism. Mitochondrial STAT3 supports RAS-dependent malignant transformation and tumor growth. However, whether pharmacological blockade of STAT3 leads… read more here.
Keywords: mutant lung; pyrvinium; kras mutant; lung cancer ... See more keywords
USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer letters"
DOI: 10.1016/j.canlet.2018.07.002
Abstract: As a newly discovered deubiquitinating enzyme, ubiquitin-specific protease 22 (USP22) is predictive of therapeutic outcomes in individual cancer patients. However, its clinical effects on malignancy and its roles in conferring resistance to EGFR-TKIs (epidermal growth… read more here.
Keywords: egfr; egfr mutant; resistance egfr; egfr tkis ... See more keywords
CT features of HER2-mutant lung adenocarcinomas
Sign Up to like & getrecommendations! Published in 2018 at "Clinical imaging"
DOI: 10.1016/j.clinimag.2018.05.028
Abstract: Objectives: To describe the radiological phenotype of HER2-mutant lung cancers on CT at presentation. Methods: Eligible patients with lung adenocarcinomas with HER2 mutations were stage-matched with two control groups (EGFR- and KRAS-mutant groups). Evaluated CT… read more here.
Keywords: her2 mutations; presence pleural; mutant lung; lung adenocarcinomas ... See more keywords
HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Oncogenesis"
DOI: 10.1038/s41389-019-0158-7
Abstract: Drug resistance and tumor heterogeneity are formidable challenges in cancer medicine, which is particularly relevant for KRAS-mutant cancers, the epitome of malignant tumors recalcitrant to targeted therapy efforts and first-line chemotherapy. In this study, we… read more here.
Keywords: mutant lung; drug; kras mutant; lung cancer ... See more keywords
‘A most malignant malady’: a rare case of laryngeal tuberculosis in epidermal growth factor receptor mutant lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Internal Medicine Journal"
DOI: 10.1111/imj.13560
Abstract: Laryngeal tuberculosis (TB) is a rare and frequently under-recognised disease. It has no pathognomonic features and can mimic many other disorders. Diagnosis is frequently delayed and can result in significant complications. We report an unusual… read more here.
Keywords: lung adenocarcinoma; mutant lung; laryngeal tuberculosis; lung ... See more keywords
IκB Kinase α Is Required for Development and Progression of KRAS-Mutant Lung Adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer research"
DOI: 10.1158/0008-5472.can-17-1944
Abstract: Although oncogenic activation of NFκB has been identified in various tumors, the NFκB-activating kinases (inhibitor of NFκB kinases, IKK) responsible for this are elusive. In this study, we determined the role of IKKα and IKKβ… read more here.
Keywords: lung adenocarcinoma; mutant lung; kras mutant; ikk ... See more keywords
LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer research"
DOI: 10.1158/0008-5472.can-18-3527
Abstract: In KRAS-mutant lung adenocarcinoma, tumors with LKB1 loss (KL) are highly enriched for concurrent KEAP1 mutations, which activate the KEAP1/NRF2 pathway (KLK). Here we investigated the biological consequences of these co-occurring alterations and explored whether… read more here.
Keywords: lung adenocarcinoma; kras mutant; lkb1 keap1; mutant lung ... See more keywords
Abstract A37: Implication of targeting YAP1 in KRAS-mutant lung cancer cells
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.hippo19-a37
Abstract: Lung cancer is the leading cause of cancer death worldwide, and it is estimated that 1.6 million deaths occur per year. Non-small cell lung cancer (NSCLC), mainly consisting of adenocarcinoma and squamous cell carcinoma, accounts… read more here.
Keywords: mutant lung; cancer cells; kras mutant; lung cancer ... See more keywords